In this episode [10.18], Medicom’s correspondent covers 5 presentations from the Heart Failure Association annual meeting, held in Belgrade, Serbia, from 17-20 May 2025.
The topics discussed are:
FINEARTS-HF confirms: indefinite need for HF medication for optimal outcomes
Withdrawal of finerenone in patients with heart failure (HF) resulted in an increased risk for cardiovascular events, data from the FINEARTS-HF trial showed. These findings support the current guidelines, which recommend the indefinite use of medication for HF to maximise outcomes.
New gene therapy for HFrEF passes phase 1 testing
The gene therapy AB-1002 was well-tolerated and associated with positive efficacy outcomes in patients with heart failure with reduced ejection fraction. The promising findings of this phase 1 study led to the development of the phase 2 GenePHIT study, which is currently enrolling patients.
High vs low positive end-expiratory pressure in IMV may impact survival
A high positive end-expiratory pressure (PEEP) is likely preferred over a low PEEP in patients with acute heart failure receiving invasive mechanical ventilation. The low PEEP was associated with higher rates of in-hospital mortality and adverse events, and so the trial was terminated early.
Promising results for novel HCM therapy
The investigational therapy EDG-7500 was generally well-tolerated and improved several disease markers in patients with hypertrophic cardiomyopathy. The safety and efficacy of this agent will be explored further.
REDICAE: Diuretics withdrawal appears feasible in stable HFrEF
Withdrawal of diuretics appeared to be feasible in stable, euvolemic outpatients with heart failure with reduced ejection fraction (HFrEF) on guideline-directed medical therapy. There was no increase in perceived dyspnoea or the incidence of HF decompensation in patients who withdrew from diuretics compared with those who kept using diuretics.
Enjoy listening!
Copyright ©2025 Medicom Medical Publishers
Posted on
Table of Contents: HFA 2025
Featured articles
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
Gene Therapy and the Future of HF Management
Artificial intelligence in HF management
Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM
New gene therapy for HFrEF passes phase 1 testing
MUSIC-HFpEF: Encouraging early results of novel gene therapy for HFpEF
Innovative Devices
FUTURE-HF: Novel IVC sensor may help control volume and improve function outcomes
C-MIC II: Cardiac microcurrent therapy in HFrEF
Updates on Finerenone
Real-world eligibility for finerenone: insights from the FIDELITY pooled analysis
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
FIVE-STAR: Mechanistic effects of finerenone in T2D plus CKD unravelled
New Therapies for Hypertrophic Cardiomyopathy
SEQUOIA-HCM: Aficamten effects consistent across regions
Large Trials, Big Impact
PRAISE-HFrEF: Is it safe to use GLP1-receptor agonists in clinically severe HF?
HELIOS-B: Health benefits of vutrisiran for ATTR-CM may increase over time
EMPEROR-Preserved: Diastolic dysfunction might predict response to empagliflozin
GALACTIC-HF: zooming in on efficacy data and subgroups
More Hot Trials from HFA
PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency?
SOGALDI-PEF: SGLT2 inhibitor plus MRA improves biomarker outcomes in HFp/mrEF
REDICAE: Diuretic withdrawal appears feasible in stable HFrEF
GLADIATOR: Anti-ulcer agent geranylgeranylacetone explored in HFpEF
High vs low positive end-expiratory pressure in IMV may impact survival
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com